fluoromisonidazole has been researched along with th 302 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheon, GJ; Kang, SY; Lee, KH; Oh, DY; Yoon, J | 1 |
| Angermeier, A; Della Manna, D; Larimer, BM; Li, Y; Reeves, KM; Song, PN; Sorace, AG; Wang, J; Yang, ES | 1 |
| Larimer, B; Lima, EABF; Reeves, K; Song, PN; Sorace, AG; Yankeelov, TE | 1 |
3 other study(ies) available for fluoromisonidazole and th 302
| Article | Year |
|---|---|
Targeting Hypoxia Using Evofosfamide and Companion Hypoxia Imaging of FMISO-PET in Advanced Biliary Tract Cancer.
Topics: Biliary Tract Neoplasms; Cell Hypoxia; Female; Humans; Male; Middle Aged; Misonidazole; Nitroimidazoles; Phosphoramide Mustards; Positron-Emission Tomography; Prospective Studies | 2021 |
Topics: Cell Hypoxia; CTLA-4 Antigen; Humans; Hypoxia; Misonidazole; Neoplasms; Nitroimidazoles; Phosphoramide Mustards; Positron-Emission Tomography; Programmed Cell Death 1 Receptor; Tumor Microenvironment | 2022 |
Predicting response to combination evofosfamide and immunotherapy under hypoxic conditions in murine models of colon cancer.
Topics: Adenocarcinoma; Animals; Cell Hypoxia; Cell Line, Tumor; Colonic Neoplasms; Disease Models, Animal; Hypoxia; Immunotherapy; Mice; Tumor Microenvironment | 2023 |